An observational study in Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by M.D. Anderson Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Adenocarcinoma, Clear Cell with a site in United States — 6 open to participants now, 13 under way, 2 of them phase 3. Adenocarcinoma, Clear Cell · United States.
Among the 36 studies in Adenocarcinoma, Clear Cell with a site in United States, this one is one of 2 that started in 2021, is the only observational one, reaches primary completion later than 4 of the 12 other live ones, and was the 31st registered.
46 studies on the registry are indexed under Adenocarcinoma, Clear Cell; 8 are open to participants now.
Browse Adenocarcinoma, Clear Cell studies →6 of the 36 studies in Adenocarcinoma, Clear Cell with a site in United States are open now. Recruiting first, the newest first:
Tufts Medical Center · Sites in United States
Ages 18+ · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+ · Women only
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
University of Utah · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Adenocarcinoma, Clear Cell studies recruiting now, 8 set no upper age limit and none stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 20 · Phase 3 6
First in 2000; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 48 across the 35 interventional studies, 70 across the 1 observational. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 36 have an industry lead sponsor. The 10 most frequent:
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
M.D. Anderson Cancer Center has 3 studies filed under Adenocarcinoma, Clear Cell — fewer than ten, so there is no comparison to draw.
4 of the studies in Adenocarcinoma, Clear Cell with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03422198Phase 3University of UtahShort Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer | 2026-11-30 |
| NCT01582204Memorial Sloan Kettering Cancer CenterEvaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma | 2027-04 |
| NCT04623502University of Texas Southwestern Medical CenterAn Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy | 2027-04-30 |
| NCT05544929Novartis PharmaceuticalsA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | 2027-10-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies in Adenocarcinoma, Clear Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to provide a comprehensive report on clinicopathologic features, immunohistochemical/biomarker testing and molecular profile of cervical clear cell carcinoma. This study may help researchers learn more about the molecular profile of cervical clear cell carcinoma.
PRIMARY OBJECTIVE:
I. To perform a retrospective clinicopathologic study on patients diagnosed and treated for clear cell carcinoma of the cervix at M D Anderson Cancer Center (MDACC) and to delineate the immunohistochemical and molecular profile of these cases.
OUTLINE:
Patients' medical records are reviewed retrospectively, and archival tumor tissue analyzed by immunohistochemistry and next generation sequencing.
Patients diagnosed with clear cell carcinoma of the cervix, from January 1, 1985 to July 1, 2020
Inclusion Criteria:
Patients' medical records are reviewed retrospectively, and archival tumor tissue analyzed by immunohistochemistry and next generation sequencing.
Other: Electronic Health Record Review · Other: Laboratory Biomarker Analysis
Medical records reviewed
Correlative studies
Clinicopathologic study on patients diagnosed and treated for clear cell carcinoma of the cervix
Time frame: through study completion, an average of 1 year
Started Aug 2021 (actual). Primary completion is estimated for Sep 2026, 61 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.